Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
find phase II dose of study drugs in pts w/hormone receptor-positive locally advanced or metastatic breast ca. find clinical benefit rate (pts who achieve a CR, PR, or SD in the first-line trt of postmenopausal pts.
3 years
Yes
Antoinette Tan, MD
Principal Investigator
UMDNJ/CINJ
United States: Institutional Review Board
040706
NCT00634634
March 2008
Name | Location |
---|---|
Cooper Hospital/University Medical Center | Camden, New Jersey 08103 |
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
Emory University | Atlanta, Georgia 30322 |
Georgetown University Hospital | Washington, District of Columbia 20007 |